Evidence map›Paper›PMID 35706816›Full record

ArticleTranslational cancer research2022

The early diagnoses and treatment of anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a patient with breast cancer: a case report.

Wei Wang, Hongjin Liu, Yinhua Liu, Qian Liu

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wei WangBreast Disease Center, Peking University First Hospital, Beijing, China.
Hongjin LiuBreast Disease Center, Peking University First Hospital, Beijing, China.
Yinhua LiuBreast Disease Center, Peking University First Hospital, Beijing, China.
Qian LiuBreast Disease Center, Peking University First Hospital, Beijing, China.
Peking University First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Paraneoplastic cerebellar degeneration (PCD) is a relatively rare complication among patients with cancers with nonmetastatic tumor manifestation, including breast cancer. A breast cancer diagnosis is usually made several months (or even years) after the onset of neurological symptoms. Case Description: In this study, we describe the early diagnosis and treatment of PCD in one patient with breast cancer. The patient's first symptom was unsteady gait, followed by dizziness and dysarthria of explosive speech. Subacute progressive ataxia symptoms, weight loss, normal imaging findings, and a lack of evidence of infection combined to lead to clinical diagnosis of PCD, and further confirmed by positron emission tomography-computed tomography (PET-CT), positive anti-Yo antibodies and core needle biopsy. Immunosuppressant therapy consisting of intravenous immunoglobulin (IVIG) and high-dose corticosteroids was effective. The patient underwent modified radical mastectomy and 2 cycles of chemotherapy, and the result suggested that treatment of the primary tumor also improved the neurological symptoms to a certain extent. At 1-year follow-up, there was no evidence of recurrence, and the patient's neurological symptoms were stable. Conclusions: Once PCD was suspected, without clear physical findings or symptoms, PET-CT should be performed for a systemic evaluation for an occult malignancy. Even if the diagnosis and treatment were timely, expectations for prognosis should not be too high.

Indexed as

autoimmunityBreast cancercase reportparaneoplastic cerebellar degeneration (PCD)

Identifiers

PMID35706816
PMCPMC9189251
OpenAlexW4231258430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.